Exelixis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 01, 2022 at 04:17 pm EDT
Share
Exelixis, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 411.74 million compared to USD 328.42 million a year ago. Net income was USD 73.21 million compared to USD 38.2 million a year ago. Basic earnings per share from continuing operations was USD 0.23 compared to USD 0.12 a year ago. Diluted earnings per share from continuing operations was USD 0.23 compared to USD 0.12 a year ago.
For the nine months, revenue was USD 1,187.15 million compared to USD 983.83 million a year ago. Net income was USD 212.46 million compared to USD 135.9 million a year ago. Basic earnings per share from continuing operations was USD 0.66 compared to USD 0.43 a year ago. Diluted earnings per share from continuing operations was USD 0.65 compared to USD 0.42 a year ago.
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
EXELIXIS, INC. 
